ChiCTR2500096386 版本V1.0 版本创建时间2025/01/22 16:40:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500096386 

最近更新日期:

Date of Last Refreshed on:

2025-01-22 16:40:27 

注册时间:

Date of Registration:

2025-01-22 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

评价Bactiseal 导管植入安全性 的回顾性、多中心登记研究

Public title:

A Multi-center, Retrospective Registry Study on the Safety of Bactiseal Catheter

注册题目简写:

English Acronym:

研究课题的正式科学名称:

评价Bactiseal 导管植入安全性 的回顾性、多中心登记研究

Scientific title:

A Multi-center, Retrospective Registry Study on the Safety of Bactiseal Catheter

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

唐华 

研究负责人:

鲍南 

Applicant:

Tang Hua 

Study leader:

Bao Nan  

申请注册联系人电话:

Applicant telephone:

+86 21 6317 9772

研究负责人电话:

Study leader's telephone:

+86 21 3862 6161

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

155021956@163.com

研究负责人电子邮件:

Study leader's E-mail:

bnscmc@shsmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区龙耀路175号

研究负责人通讯地址:

中国 上海市 浦东新区 东方路1678号

Applicant address:

No.175 Longyao Road, Xuhui District, Shanghai

Study leader's address:

1678 Dongfang Road, Pudong New Area, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

英特格拉生命科技(上海)有限公司

Applicant's institution:

Integra Life Sciences (Shanghai) Co., Ltd

研究负责人所在单位:

上海交通大学医学院附属上海儿童医学中心

Affiliation of the Leader:

Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University School of Medicine

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SCMCIRB-L202413-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学医学院附属上海儿童医学中心伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-18 00:00:00

伦理委员会联系人:

李岚

Contact Name of the ethic committee:

Li Lan

伦理委员会联系地址:

中国 上海市 浦东新区 东方路1678号

Contact Address of the ethic committee:

1678 Dongfang Road, Pudong New Area, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 3862 6161

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属上海儿童医学中心

Primary sponsor:

Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University School of Medicine

研究实施负责(组长)单位地址:

中国 上海市 浦东新区 东方路1678号

Primary sponsor's address:

1678 Dongfang Road, Pudong New Area, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

英特格拉生命科技(上海)有限公司

具体地址:

上海市徐汇区龙耀路175号

Institution
hospital:

Integra Life Sciences (Shanghai) Co., Ltd

Address:

No.175 Longyao Road, Xuhui District, Shanghai

经费或物资来源:

自筹

Source(s) of funding:

self-funded

Target disease:

hydrocephalus

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

此项研究的主要目的是收集植入英特格拉生命科技制造公司生产的导管(商品名Bactiseal导管)受试者的安全性信息。器材安全性将根据植入分流导管后受试者在2年内发生的所有不良事件进行评价。  

Objectives of Study:

This study aims to continuously evaluate the safety of subjects implanted with a catheter (trade name: Bactiseal) produced by Integra LifeSciences Production Corporation. Device safety will be assessed based on all the adverse events that occurred within 2 years after implanted the catheter.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

入选符合下列所有入选标准的受试者: 1. 经研究中心伦理委员会批准豁免获得知情同意,或受试者或其法定代理在入选前签署了知情同意书; 2. 受试者符合使用Bactiseal分流导管的适应症; 3. 在入组时,受试者植入Bactiseal分流导管至少2年。

Inclusion criteria

Subjects who meet all the following inclusion criteria will be enrolled: 1. The informed consent is exempted by the Ethics Committee of a research center. Or a subject or his/her legal representative signed the informed consent form (ICF) prior to the enrollment. 2. A subject had an indication suitable to use Bactiseal Catheter. 3. A subject implanted hydrocephalus shunt catheter for at least 2 years at the time of enrollment.

排除标准:

排除符合下列任何排除标准的受试者: 1. 受试者不属于分流导管适应症的应用人群; 2. 受试者已知对植入导管或成分过敏,包括硅胶管及其它成分; 3. 经研究者综合判断,受试者植入分流导管时存在植入部位感染,如脑室炎、脑膜炎、 腹膜炎、皮肤感染等; 4. 受试者同时植入不包括Bactiseal导管的其他分流导管; 5. 受试者存在分流手术的禁忌症; 6. 受试者存在未纠正的凝血功能障碍或任何出血性疾病。

Exclusion criteria:

Subjects who meet any of the following exclusion criterion are excluded: 1. A subject didn't have an indication suitable to use the catheter. 2. A subject was known to be allergic to a component or ingredient of the catheter to be implanted, including silicone catheter, rifampicin, and clindamycin. 3. According to the comprehensive judgment of an investigator, a subject had an infection of the implant site when the shunt is implanted, such as ventriculitis, meningitis, peritonitis, and local implant skin infection. 4. A subject was simultaneously implanted with another shunt catheter different from Bactiseal Catheter. 5. A subject had a contraindication of the shunt operation. 6. A subject had uncorrected coagulopathy or any bleeding disorder.

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-10-15 00:00:00 To 2025-02-28 00:00:00  

干预措施:

Interventions:

组别:

观察组

样本量:

200

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing  

City:

 

单位(医院):

北京医院 

单位级别:

三甲 

Institution
hospital:

Beijing Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三甲 

Institution
hospital:

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China  

Province:

Sichuan  

City:

 

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China  

Province:

Beijing  

City:

 

单位(医院):

首都医科大学宣武医院 

单位级别:

三甲 

Institution
hospital:

Xuanwu Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China  

Province:

Guangdong  

City:

 

单位(医院):

南方医科大学珠江医院 

单位级别:

三甲 

Institution
hospital:

Zhujiang Hospital, Southern Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

黑龙江 

市(区县):

 

Country:

China  

Province:

Heilongjiang  

City:

 

单位(医院):

哈尔滨医科大学附属第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Harbin Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China  

Province:

Hubei  

City:

 

单位(医院):

武汉大学中南医院 

单位级别:

三甲 

Institution
hospital:

Zhongnan Hospital of Wuhan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

受试者植入Bactiseal分流导管后2年内与导管相关的感染率

指标类型:

主要指标

Outcome:

Incidence of Bactiseal shunt catheter related infection within 2 years post implant

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

受试者植入Bactiseal分流导管后2年内不良事件发生率

指标类型:

主要指标

Outcome:

Incidence of adverse events of a subject within 2 years post implant Bactiseal Shunting catheter

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表文章后;邮件联系

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After publishing the paper; Contact by email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF, EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-01-22 16:40:27